Pfizer's First Quarter , Profits Blast Past, 2022 Forecast.
ABC reports that Pfizer's COVID-19 vaccine and treatment
sales helped propel the pharmaceuticals company
beyond Wall Street's first quarter expectations. .
Pfizer's coronavirus vaccine
Comirnaty raked in over $13 billion
in sales for the first quarter. .
Pfizer's coronavirus vaccine
Comirnaty raked in over $13 billion
in sales for the first quarter. .
The vaccine has remained
Pfizer's top selling product
for almost the last year. .
The drugmaker's pill treatment
Paxloid reportedly added an additional
$1.5 billion to the company's sales. .
ABC reports that Pfizer's, profits grew 61% , in the first quarter. .
On May 3, the company posted
a net income of $7.86 billion and first
quarter adjusted earnings of $1.62 per share. .
The results easily exceeded
the $1.49 increase predicted
by industry analysts. .
Compared to the same time last year,
the company's revenue skyrocketed 77% , to reach $25.66 billion. .
According to ABC, the drugmaker
expects the company's total revenue in 2022
to reach between $98 billion and $102 billion. .
Pfizer's COVID vaccine launched late
in 2020 and quickly became the company's
top selling product by the second quarter of 2021.
In December of 2021,
Pfizer's stock reached an
all-time high of $61.71 per share.